公开(公告)号：US20250163370A1

公开(公告)日：2025-05-22

申请号：US18836137

申请日：2023-02-06

Applicant: OSAKA UNIVERSITY

Inventor： Masahiro KINOOKA ,  Meehae KIM ,  Yukako GUJINAGA

IPC: C12N5/079

Abstract: A method for producing a retinal pigment epithelial (RPE) cell is disclosed. The method includes promoting a differentiation induction from a pluripotent stem cell into an RPE cell by culturing the pluripotent stem cell in a medium containing an E-cadherin inhibitor. The medium may further contain a differentiation inducer. The pluripotent stem cell may be an embryonic stem(ES) cell or an induced pluripotent stem (iPS) cell.

公开(公告)号：US20250163369A1

公开(公告)日：2025-05-22

申请号：US18836633

申请日：2023-02-06

Applicant: OSAKA UNIVERSITY

Inventor： Masahiro KINOOKA ,  Meehae KIM ,  Yukako FUJINAGA

IPC: C12N5/071 ,  C12N5/00

Abstract: An agent for directional control of differentiation induction of a pluripotent stem cell, which contains an E-cadherin inhibitor, and its uses are disclosed. A method for controlling the directionality of differentiation induction of a pluripotent stem cell is also disclosed. The method includes a step of culturing a pluripotent stem cell in a medium comprising an E-cadherin inhibitor.

公开(公告)号：US20250042954A1

公开(公告)日：2025-02-06

申请号：US18910921

申请日：2024-10-09

Applicant: OSAKA UNIVERSITY

Inventor： Yukako FUJINAGA ,  Sho AMATSU ,  Masahiro KINOOKA

IPC: C07K14/33 ,  C12N15/85

Abstract: A nucleic acid encoding a miniatureized hemagglutinin complex protein, wherein the miniaturized hemagglutinin complex protein has function inhibitory activity against E-cadherin, and wherein the miniaturized hemagglutinin complex protein is selected from the group consisting of: (1) mini-HA consisting of HA1 subcomponent of SEQ ID NO: 10, HA2 subcomponent of SEQ ID NO: 4, and HA3 subcomponent fragment of SEQ ID NO: 2, (2) FL(2+3)-C consisting of HA2 subcomponent of SEQ ID NO: 4 and HA3 component with Strep-Tag (C-terminus) of SEQ ID NO: 44, (3) linked-mini (2+3)/BB of SEQ ID NO: 47, (4) linked-mini (2+3)/CB of SEQ ID NO: 48, (5) linked-mini (2+3)/CB-YFDY of SEQ ID NO: 49, and (6) linked-mini (2+3)/CB-LD/YFDY of SEQ ID NO: 50.

公开(公告)号：US20210122790A1

公开(公告)日：2021-04-29

申请号：US16766596

申请日：2018-11-22

Applicant: NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY ,  OSAKA UNIVERSITY

Inventor： Yukako FUJINAGA ,  Sho AMATSU ,  Masahiro KINOOKA

IPC: C07K14/33 ,  C12N15/85

Abstract: The present invention provides a miniaturized hemagglutinin complex protein having function inhibitory activity against E-cadherin, wherein (a) all or a part of at least HA1 subcomponent, and/or a part of HA3 subcomponent are/is deleted, (b) regions in HA2 and HA3 subcomponents that contribute to binding with E-cadherin are present, and (c) the HA3 subcomponent is derived from Clostridium botulinum type A or type B, and an E-cadherin function inhibitor containing the hemagglutinin complex protein.

公开(公告)号：US20190250073A1

公开(公告)日：2019-08-15

申请号：US16237888

申请日：2019-01-02

Applicant: NIHON KOHDEN CORPORATION ,  OSAKA UNIVERSITY

Inventor： Hodaka MAKINO ,  Hirotsugu KUBO ,  Masahiro KINOOKA

IPC: G01N1/10 ,  G01N1/34 ,  G01N1/44

CPC classification number: G01N1/10 ,  G01N1/34 ,  G01N1/44

Abstract: An aseptic sampling flow path kit to be applied to an isolator having a liquid delivery port includes a sampling section, a first flow path that communicates with the sampling section, and that connects an inside of the isolator to an outside of the isolator through the liquid delivery port, and at least one one-way valve which is disposed in the first flow path, and that limits flow of fluid in the first flow path to a direction from the sampling section toward the liquid delivery port. In the kit, at least a part of the first flow path is a germicidal flow path to which a germicidal unit is applicable.

公开(公告)号：US20190247842A1

公开(公告)日：2019-08-15

申请号：US16239088

申请日：2019-01-03

Applicant: NIHON KOHDEN CORPORATION ,  OSAKA UNIVERSITY

Inventor： Hodaka MAKINO ,  Hirotsugu KUBO ,  Tetsuya OGAWA ,  Masahiro KINOOKA

IPC: B01L1/02 ,  B01L3/00

CPC classification number: B01L1/025 ,  B01L3/502 ,  B01L3/565 ,  B01L3/567 ,  B01L2300/048 ,  B01L2300/049 ,  B01L2300/10 ,  B01L2400/06 ,  B01L2400/0622

Abstract: An aseptic sampling apparatus includes an isolator, a liquid delivery port that is disposed in the isolator, a sampling section that is disposed inside the isolator, a first flow path that communicates with a discharge flow path of the sampling section, and that connects an inside and outside of the isolator to each other through the liquid delivery port, a fluid supplying unit that supplies a fluid to the sampling section, a gas supplying unit that communicates with the fluid supplying unit, and a seal member that prevents the fluid supplied from fluid supplying unit to the discharge flow path from leaking.

公开(公告)号：US20190078044A1

公开(公告)日：2019-03-14

申请号：US16084283

申请日：2016-03-16

Applicant: Shimadzu Corporation ,  Yokohama City University ,  Osaka University ,  Kuraray Co., Ltd.

Inventor： Tomoki OHKUBO ,  Masaki KANAI ,  Hirohisa ABE ,  Hideki TANIGUCHI ,  Masahiro KINOOKA ,  Goro KOBAYASHI ,  Takanori TAKEBE

IPC: C12M3/06 ,  C12M3/00

Abstract: A cell culture container includes a storage container, a cell culture area, a culture solution supply unit, and a discharge unit. The cell culture area is a region for culturing cells, and is provided in the storage container. The culture solution supply unit supplies the culture solution into the cell culture area at a flow rate equal to or less than a predetermined flow rate. The discharge unit discharges the liquid in the cell culture area to the outside of the storage container. A rectification unit is a structure in which a plurality of outflow ports are uniformly arranged in a direction perpendicular to the flow direction of the culture solution from the culture solution supply unit to the discharge unit.